The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
about
Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and EribulinFrequent amplification of receptor tyrosine kinase genes in welldifferentiated/ dedifferentiated liposarcoma.Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma.Spontaneous pneumothorax in diffuse cystic lung diseases.Pharmacokinetic drug evaluation of pazopanib for the treatment of uterine leiomyosarcomas.Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study().Therapeutic applications of histone deacetylase inhibitors in sarcoma.Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations.Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma.Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma.Neutrophil-to-lymphocyte ratio after pazopanib treatment predicts response in patients with advanced soft-tissue sarcoma.Leiomyosarcoma of the stomach with metastasis to the liver: a case report with review of the literature.Current status of immunotherapy for sarcomas.Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care.Phase 1/2 study of immunotherapy with dendritic cells pulsed with autologous tumor lysate in patients with refractory bone and soft tissue sarcoma.Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas.Clinical outcomes of patients with epithelioid sarcomas: impact and management of nodal metastasis.Treatment Patterns and Survival among Adult Patients with Advanced Soft Tissue Sarcoma: A Retrospective Medical Record Review in the United Kingdom, Spain, Germany, and France.
P2860
Q33890846-BACBB3FC-1E7C-444A-986C-2E0692224A11Q37706527-045BDE21-2B81-4888-ABBE-0A0E89120B16Q38654374-81A759C3-5318-4AE9-8D1F-FA83A443C5D3Q38673770-794DDA6C-6419-4898-9E7C-0C04DBE905CFQ39415429-C3BB02CD-AC37-4FD9-A5D5-754EA2A197D7Q39444949-3C00BB60-AEC2-44DA-BAFE-BFB8949153F8Q39450827-B5A1D9A6-6869-4B80-8A0E-22E02549EAC5Q41105379-9AFAA8FD-BFD2-47E4-BB51-E287D76A566CQ42363585-5A3F6DA8-2BC7-4498-B492-276F8BF8555CQ46688699-EC931FCA-9F57-4251-89E3-7BD38C6596BDQ47685069-B6C5541B-A7E3-4967-8403-449A223F18E3Q47705942-112E86B7-FD88-4654-95B1-FCEA024E574CQ49557938-F00AA928-477A-4E3F-B272-6F1D0DB749B8Q50133191-0551165D-67EB-4C74-965C-37663B961217Q51120716-43301DED-DCC7-42C4-BF1A-8225A955269DQ52671439-378B75D3-5AD3-42EC-BD19-C4B8537C5125Q53116344-6C0E8753-3E24-4AE7-B586-7FB2EA675612Q55418407-8829CA8F-C2E4-4AD3-959C-4384BA66D2E7
P2860
The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
description
2016 nî lūn-bûn
@nan
2016 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մարտին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
The clinical outcome of pazopa ...... l Oncology Group (JMOG) study.
@ast
The clinical outcome of pazopa ...... l Oncology Group (JMOG) study.
@en
type
label
The clinical outcome of pazopa ...... l Oncology Group (JMOG) study.
@ast
The clinical outcome of pazopa ...... l Oncology Group (JMOG) study.
@en
prefLabel
The clinical outcome of pazopa ...... l Oncology Group (JMOG) study.
@ast
The clinical outcome of pazopa ...... l Oncology Group (JMOG) study.
@en
P2093
P2860
P356
P1433
P1476
The clinical outcome of pazopa ...... al Oncology Group (JMOG) study
@en
P2093
Akihiko Matsumine
Akihiro Sudo
Akira Kawai
Hideshi Sugiura
Hiroaki Hiraga
Nobuhito Araki
Shogen Boku
Takafumi Ueda
Takahiro Goto
Taketoshi Yasuda
P2860
P304
P356
10.1002/CNCR.29961
P407
P50
P577
2016-03-11T00:00:00Z